{"entity":{"id":"lgr5-gene","kind":"target","name":"LGR5","aka":["leucine rich repeat containing G protein-coupled receptor 5","Leucine-rich repeat-containing G protein-coupled receptor 5","HG38","GPR67","GPR49"],"tldr":"LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.","summary":"Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Fluorouracil. In OnCo, 1 product record names it (Petosemtamab).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:4504","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4504"},{"label":"UniProt O75473","url":"https://www.uniprot.org/uniprotkb/O75473/entry"},{"label":"NCBI Gene 8549","url":"https://www.ncbi.nlm.nih.gov/gene/8549"},{"label":"Ensembl ENSG00000139292","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139292"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["colorectal","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["petosemtamab"],"companies":[],"institutions":[],"pathways":["wnt"],"terms":[],"trials":["nct05759728"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants; a membrane or secreted protein (UniProt keywords) that 1 antibody-based OnCo product name. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Oral Squamous Cell Carcinoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"LGR5","role":["drug-target","biomarker","antigen"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:4504","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4504","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O75473","url":"https://www.uniprot.org/uniprotkb/O75473/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene LGR5","url":"https://civicdb.org/features/6772","note":"3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Oral Squamous Cell Carcinoma, Sarcoma (GraphQL API, CC0)"}],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 1 antibody (Petosemtamab) aim at the antigen, which HPA finds stained high in 3 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA LGR5: RNA tissue enhanced (fallopian tube 16 nTPM, placenta 18 nTPM, skeletal muscle 21 nTPM); high antibody staining in 3 normal tissues; highest cancer staining cervical cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Sarcomas (soft tissue, bone, GIST)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas LGR5 tissue","url":"https://www.proteinatlas.org/ENSG00000139292-LGR5/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas LGR5 pathology","url":"https://www.proteinatlas.org/ENSG00000139292-LGR5/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000139292 associations","url":"https://platform.opentargets.org/target/ENSG00000139292/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:4504","ensembl":"ENSG00000139292","uniprot":"O75473","entrez":"8549","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: McDonald et al, Biochem. Biophys. Res. Commun, 1998, \"Identification and cloning of an orphan G protein-coupled receptor of the glycoprotein hormone receptor subfamily\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9642114/","biology":"Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Location: Cell membrane; Golgi apparatus, trans-Golgi network membrane (UniProt). Locus 12q21.1 (HGNC).","whereFound":["Colorectal cancer: CIViC evidence names this disease","Sarcomas: CIViC evidence names this disease"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/lgr5-gene/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/"}],"pathway":[{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/"}],"trial":[{"id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/"}]}}